The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples